Intel
INTC
Alibaba
BABA
Advanced Micro Devices
AMD
Netflix
NFLX
Oracle
ORCL
US Stock MarketDetailed Quotes
ENLV Enlivex Therapeutics
- 1.150
- -0.070-5.74%
Close Mar 17 16:00 ET
25.29MMarket Cap-1.17P/E (TTM)
1.220High1.100Low177.40KVolume1.220Open1.220Pre Close205.00KTurnover1.10%Turnover RatioLossP/E (Static)21.99MShares4.59052wk High0.95P/B18.47MFloat Cap0.81052wk Low--Dividend TTM16.06MShs Float44.900Historical High--Div YieldTTM9.84%Amplitude0.810Historical Low1.155Avg Price1Lot Size
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Enlivex Therapeutics Stock Forum
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Monday, 17th March at 8:00 am
Nes-Ziona, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a notice of allowance for patent a...
$AtlasClear (ATCH.US)$
$Icon Energy (ICON.US)$
$Sharps Technology (STSS.US)$
$Enlivex Therapeutics (ENLV.US)$
Still trying to find an original Gem but I've got nothing as of right now. I will likely observe action on Monday and be patient with an entry if I enter any at all.
Can Enlivex's Osteoarthritis Treatment Disrupt a Multi-Billion Dollar Market? 6-Month Data Impresses
Benzinga· 1 min ago
Statistically significant 47.0% average reduction of reported pain (P=0.0001) compared to average pain level at baseline46% improvement in joint function and 40% improvement in joint stiffness83% of the patients were still considered as responders to treat...
Enlivex Takes Legal Action Against Market Manipulation as Stock Trading Continues Uninterrupted
2 MINUTES AGO, 6:20 AM EST
VIA GLOBENEWSWIRE
Ness-Ziona, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, alerts investors and the public that a completely false and misleading report regarding the Company was intentionally published this morning by the website Tipranks.com claiming ...
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Friday, 10th January at 9:00 am
ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ: ENLV) and bioAffinity Technologies, Inc. (NASDAQ: BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m....
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Wednesday, 11th December at 8:30 am
Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase ...
Enlivex Therapeutics Receives Regulatory Authorization From Israeli Ministry Of Health For Initiation Of Phase I Trial Evaluating Allocetra In Patients With TMJ Osteoarthritis
No comment yet